LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS

LSL Pharma Group Reports Record Q1-2026 Revenues while positioning for improved profitability following Steri-Med Pharma production resumption. Launch of new eye-drop portfolio planned for the second quarter of 2026. Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market. BOUCHERVILLE, QC , May 25, 2026 /CNW/ - LSL PHARMA GROUP INC . (TSXV: LSL ) (the " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2026 ("Q1-26"). All amounts are presented in millions ("M") of Canadian dollars. Q1-26 Corporate and Financial Highlights Record quarterly consolidated revenues, including full quarter contribution from Laboratoire Du-Var ("Du-Var") and Juno OTC acquired on January 1 st , 2026 and to be presented as 3 rd business segment; Strong Eye-Care revenues show significant market share gains in Canada; Q1-26 profitability temporarily impacted by the three-month Steri-Med Pharma (Steri-Med) production pause, with full production activities having resumed in April 2026; Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market; Commissioning of new state-of-the-art sterile ointment manufacturing line on track for commercial production by Q1-27; Development of three (3) new ointment products initiated for regulatory filings during FY-27. Binding term sheet signed with Instapill Private Limited ("Instapill") for the Canadian rights to private label Loratadine 10 mg Orally Disintegrating Tablets (ODT), a bioequivalent product to Claritin® Rapid Dissolve TM ; Revolving credit facility increased from $7.5M to $11M; "During the first quarter of 2026, we saw the positive impact of the recent acquisitions of Juno OTC and Du-Var on our operating results and the diversification of our business platform. Whil